The US Supreme Court ruled yesterday, June 4, that pharmaceutical company Hikma’s generic cardiovascular drug does not infringe global biopharmaceutical company Amarin’s patents covering its drug ...
WASHINGTON, June 4 (Reuters) - Drugmaker Hikma's (HIK.L), opens new tab generic version of Amarin Pharma's (AMRN.O), opens new tab cardiovascular medication Vascepa did not infringe Amarin's patents, ...
Most disputes between pharmaceutical companies and generic drugmakers end in settlements. Five years of class-action litigation over a Takeda Pharmaceutical gastrointestinal drug culminated this week ...
Hims & Hers Health (HIMS) on Thursday announced the launch of generic versions of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy semaglutide through its telehealth platform in Canada. The ...
The Trump administration is joining forces with Mark Cuban’s Cost Plus Drugs, Amazon Pharmacy, and GoodRx to add generic medications to the direct-to-consumer drug sales website, TrumpRx, in an ...
Americans are unlikely to see generic versions of semaglutide — the active ingredient in Novo Nordisk’s Ozempic and Wegovy — until at least the end of 2031, according to a May 13 NBC News report. Novo ...
India got it earlier this year, and Canada approved it last month. But when is the United States going to get a generic version of Ozempic? Limited time: Save 25% on NBC News subscription Get ...
Dr. Reddy's Laboratories (NVO) will launch its off-patent version of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy Ozempic in Canada within the “next few days,” becoming the first to sell a generic ...
The chief executive of generic-drug maker Sandoz SDZ0.31%increase; up pointing triangle Group expects the market for unbranded versions of popular weight-loss medicines to be big. Just how big, though ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The day has ...
A Supreme Court case heard this week could give brand-name drugmakers longer monopolies, delay generic competition, and leave patients paying higher prices. When it comes to generic medications, ...
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use has recommended granting a marketing authorisation for Palbociclib Viatris (palbociclib, Viatris Limited) for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results